Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Income from Continuing Operations (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Income from Continuing Operations for 7 consecutive years, with 6652000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Income from Continuing Operations rose 28.66% to 6652000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 38243000.0, a 23.25% increase, with the full-year FY2024 number at 38243000.0, up 21.66% from a year prior.
  • Income from Continuing Operations was 6652000.0 for Q4 2024 at Actinium Pharmaceuticals, up from 11568000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5075000.0 in Q2 2021 to a low of 24948376.0 in Q4 2021.
  • A 4-year average of 10252336.0 and a median of 9561500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 54.74% in 2022, then tumbled 124.32% in 2023.
  • Actinium Pharmaceuticals' Income from Continuing Operations stood at 24948376.0 in 2021, then surged by 54.74% to 11291000.0 in 2022, then rose by 17.42% to 9324000.0 in 2023, then grew by 28.66% to 6652000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Income from Continuing Operations are 6652000.0 (Q4 2024), 11568000.0 (Q3 2024), and 11353000.0 (Q2 2024).